Merck & Co., Inc.
MRK
Clasificación en acciones
#38
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Precio por acción
$148.36
Capitalización bursátil
$366.03B
Cambio (1 día)
3.31%
Cambio (1 año)
71.87%
País
US
Comercio Merck & Co., Inc. (MRK)
Categoría
Healthcare
Ratio P/E de Merck & Co., Inc. (MRK)
Ratio P/E al October 2026 TTM: 116.96
Según los últimos informes financieros y el precio de las acciones de Merck & Co., Inc., el P/E actual (TTM) de la empresa es 116.96. Al final de 2024, la empresa tenía un P/E de 14.72.
Historial del ratio P/E de Merck & Co., Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 116.96 | 708.83% |
| 2025 | 14.46 | -1.74% |
| 2024 | 14.72 | -98.11% |
| 2023 | 778.71 | 3,924.61% |
| 2022 | 19.35 | 30.21% |
| 2021 | 14.86 | -46.79% |
| 2020 | 27.92 | 23.57% |
| 2019 | 22.60 | -25.59% |
| 2018 | 30.37 | -49.75% |
| 2017 | 60.43 | 53.54% |
| 2016 | 39.36 | 24.80% |
| 2015 | 31.54 | 144.60% |
| 2014 | 12.89 | -59.36% |
| 2013 | 31.72 | 65.59% |
| 2012 | 19.16 | 9.91% |
| 2011 | 17.43 | -85.89% |
| 2010 | 123.55 | 2,069.42% |
| 2009 | 5.70 | -28.19% |
| 2008 | 7.93 | -78.40% |
| 2007 | 36.72 | 79.85% |
| 2006 | 20.42 | 41.90% |
| 2005 | 14.39 | 23.34% |
| 2004 | 11.67 | -19.12% |
| 2003 | 14.42 | -15.38% |
| 2002 | 17.04 | -3.27% |
| 2001 | 17.62 | -41.63% |
| 2000 | 30.19 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 40.53 | -65.35% |
US
|
|
| 38.50 | -67.09% |
US
|
|
| 79.88 | -31.70% |
US
|
|
| 22.25 | -80.98% |
CH
|
|
| 22.23 | -80.99% |
CH
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.